Zogenix, Inc.  

(Public, NASDAQ:ZGNX)   Watch this stock  
Find more results for ZGNX
+1.85 (13.02%)
After Hours: 15.53 -0.53 (-3.31%)
Nov 25, 4:10PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.28 - 16.09
52 week 8.64 - 21.65
Open 14.28
Vol / Avg. 331,670.00/367,667.00
Mkt cap 351.85M
P/E     -
Div/yield     -
EPS -2.55
Shares 24.76M
Beta 1.98
Inst. own 91%
Nov 18, 2015
Zogenix Inc at Stifel Healthcare Conference
Nov 9, 2015
Q3 2015 Zogenix Inc Earnings Call
Nov 9, 2015
Q3 2015 Zogenix Inc Earnings Release
Sep 30, 2015
Zogenix Inc at Leerink Partners Rare Disease Roundtable - Webcast
Sep 10, 2015
Zogenix Inc at Wells Fargo Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -142.34% 21.19%
Operating margin -132.47% -52.54%
EBITD margin - -240.69%
Return on average assets -18.32% 5.45%
Return on average equity -34.96% 23.30%
Employees 59 -
CDP Score - -


12400 High Bluff Dr Ste 650
SAN DIEGO, CA 92130-3006
United States - Map
+1-858-2591165 (Phone)
+1-858-2591166 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Zogenix, Inc. (Zogenix) is a pharmaceutical company, which is engaged in development and commercialization of therapies for people with central nervous system (CNS) disorders. The Company focuses on the areas of pain, epilepsy and schizophrenia. It is engaged in the development of Relday, a product candidate for the treatment of schizophrenia. The Company develops ZX007, an abuse-deterrent tablet formulation of single entity, extended-release hydrocodone. The Company commercializes Sumavel DosePro (sumatriptan injection), a needle-free delivery system. Sumavel DosePro offers the administration of sumatriptan for the acute treatment of migraine and cluster headache. The Company sells Sumavel DosePro to wholesale pharmaceutical distributors, pharmacies and hospitals.

Officers and directors

Cam L. Garner Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Stephen J. Farr Ph.D. President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Ann D. Rhoads Chief Financial Officer, Executive Vice President, Treasurer, Secretary
Age: 53
Bio & Compensation  - Reuters
Gail M. Farfel Ph.D. Executive Vice President, Chief Development Officer
Age: 51
Bio & Compensation  - Reuters
Bradley S. Galer M.D. Executive Vice President and Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
Thierry J P Darcis Executive Vice President and General Manager of Europe of Brabant Pharma Ltd.
Bio & Compensation  - Reuters
James B. Breitmeyer M.D., Ph.D. Director
Age: 61
Bio & Compensation  - Reuters
Roger L. Hawley Director
Age: 62
Bio & Compensation  - Reuters
Erle T. Mast Independent Director
Age: 52
Bio & Compensation  - Reuters
Mark C. Wiggins Independent Director
Age: 59
Bio & Compensation  - Reuters